Search results for

Once the Unified Patent Court is up and running, patent owners and defendants will have some interesting choices to make about representation

A recent Intellectual Ventures lawsuit filed with a companion ITC complaint may be a sign of what is to come in patent assertion entity litigation, with one observer describing it as “a formidable new change”. The ITC has now instituted the investigation against car manufacturers and parts makers

In Helsinn v Teva, the Federal Circuit has ruled the America Invents Act did not change the meaning of “on sale” and the bar applies if the existence of the sale is public, even if the details of the invention are not publicly disclosed

A well-functioning patent system should provide users and third parties with legal certainty. One pillar of legal certainty is of course a high quality patent which will stand up in court, but another is timeliness. The EPO explains its latest initiative

Purdah delays UK ratification plans; Germany makes progress with ratification; Belgium consents to UPCA Protocol; and draft UPC Rules of Procedure published

The shortlist for the seventh annual Euromoney Legal Media Group Europe Women in Business Law Awards has been announced. For the 2017 nominees, please see below.

We round up news from Bristows, Cleveland Scott York, Dentons, Bryan Cave and Simmons & Simmons

It is well known that the EPO generally applies a rather strict approach when examining whether or not amendments made after filing extend beyond the contents of the application as filed. One frequently occurring type of claim amendment is the replacement or removal of a feature from a claim. According to a landmark decision, T 331/87 of 1989, the replacement or removal of a feature may not violate the provision governing added subject-matter (article 123(2) EPC) if the skilled person would directly and unambiguously recognise that:

Sarah Wright and Kaisa Patsalides explore whether designs originating from the UK can still qualify for EU design rights in a post-Brexit world, in light of conflicting interpretations among EU courts on the meaning of “first making available within the Community”

After its product patent had expired, the brand name pharmaceutical company sued generic drug manufacturers based on a manufacturing process patent. On March 24 2017, the Supreme Court affirmed infringement under the doctrine of equivalents (DOE) for the medicinal compound's manufacturing process patent.